Chris's questions to Axsome Therapeutics Inc (AXSM) leadership • Q1 2025
Question
Chris, on behalf of Joel Beatty from Baird, asked about Axsome's plans for the recent SYMBRAVO data in CGRP non-responders, specifically if it would be pursued as a new indication or label expansion. He also inquired about the status of pursuing a label expansion for SYMBRAVO in adolescents.
Answer
Ari Maizel, CCO, explained that while the CGRP data is compelling for clinicians, the company is not currently seeking to add it to the label as a new indication but will communicate the data through medical affairs and compliant promotional activities. Mark Jacobson, COO, confirmed that the pediatric development work for SYMBRAVO is underway as agreed with the FDA.